Ivantis company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ivantisinc.com

Founded Year

2007

Stage

Acquired | Acquired

Total Raised

$136.3M

Valuation

$0000 

About Ivantis

Ivantis designs, develops and commercializes new technologies to treat eye disease. The company aims to develop new and effective solutions for ophthalmology specialists and the millions worldwide who are affected by this debilitating and sight-stealing disease.On November 8th, 2021, Ivantis was acquired by Alcon at a valuation of $475M.

Ivantis Headquarter Location

38 Discovery Suite 150

Irvine, California, 92618,

United States

949-600-9650

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ivantis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ivantis is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,620 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

Ivantis Patents

Ivantis has filed 56 patents.

The 3 most popular patent topics include:

  • Eye surgery
  • Ophthalmology
  • Diseases of the eye and adnexa
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/12/2016

12/14/2021

Diseases of the eye and adnexa, Ophthalmology, Eye surgery, Glaucoma, Sensors

Grant

Application Date

8/12/2016

Grant Date

12/14/2021

Title

Related Topics

Diseases of the eye and adnexa, Ophthalmology, Eye surgery, Glaucoma, Sensors

Status

Grant

Latest Ivantis News

Alcon Reports First Quarter 2022 Results

May 10, 2022

Strong quarterly sales of $2.2 billion, up 14% or 18% constant currency Double-digit growth in net sales in both Surgical and Vision Care Updated 2022 full year outlook Ad Hoc Announcement Pursuant to Art. 53 LR May 10, 2022 04:30 PM Eastern Daylight Time GENEVA--( BUSINESS WIRE )--Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the first quarter ended March 31, 2022. For the first quarter of 2022, worldwide sales were $2.2 billion, an increase of 14% on a reported basis and 18% on a constant currency basis(2), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.34 and core diluted earnings per share of $0.68. 0.49 "We saw a strong start to the year and our first quarter results demonstrate the continued strength of our innovative product portfolio and commercial execution," said David J. Endicott, Alcon's Chief Executive Officer. "The Alcon team delivered double-digit sales growth in both our franchises, which drove operating leverage and improved profitability across the business." Mr. Endicott continued, "While we are pleased with these results, we continue to expect broader headwinds, including inflation and foreign exchange pressures, to persist. Despite this, we are increasing our constant currency growth outlook for 2022 based on our strong underlying business and growing market shares. I want to thank our 24,000 associates for their continued commitment and dedication to helping people see brilliantly." First quarter 2022 results Worldwide sales for the first quarter 2022 were $2.2 billion, an increase of 14% on a reported basis and 18% on a constant currency basis, compared to the first quarter of 2021. Sales in both Surgical and Vision Care benefited from product innovation, improvements across geographies reflecting continuing recovery from the COVID-19 pandemic and sales from recent acquisitions. Surgical sales also included a one-time benefit related to implantables. The following table highlights net sales by segment for the first quarter of 2022:   Double-digit growth in Surgical driven by implantables and consumables Surgical net sales of $1.3 billion, which include implantables, consumables and equipment/other, increased 17%, or 22% on a constant currency basis, compared to the first quarter of 2021. Implantables growth reflected ongoing adoption of advanced technology intraocular lenses, led by Vivity, and sales of the Hydrus Microstent following the recent acquisition of Ivantis. Implantables sales also included a one-time benefit in South Korea ahead of an insurance reimbursement change for presbyopia correcting intraocular lenses that accounted for approximately 8% (cc) of implantables growth during the quarter. Consumables growth primarily reflected higher procedure volumes due to improving market conditions. Growth in equipment/other was primarily driven by demand for cataract equipment. Double-digit growth in Vision Care driven by contact lenses and Systane Vision Care net sales of $0.9 billion, which include contact lenses and ocular health, increased 10%, or 14% on a constant currency basis, compared to the first quarter of 2021. Contact lens sales benefited from growth in silicone hydrogel contact lenses, including the Precision1 and Dailies Total1 product families and Total30. Growth in ocular health was led by demand for Systane dry eye and Simbrinza glaucoma eye drops, as well as improvements in select international markets, partially offset by declines in contact lens care. Operating income First quarter 2022 operating income was $246 million and operating margin was 11.3%. Operating margin increased as a result of improved operating leverage from higher sales, including the one-time benefit in South Korea referenced above. This was partially offset by increased inflationary impacts, higher amortization for intangible assets due to recent acquisitions and a provision for a legal settlement. First quarter 2022 operating income includes net charges of $146 million for the amortization of certain intangible assets, as well as a provision for a legal settlement. Excluding these and other adjustments, first quarter 2022 core operating income was $448 million. First quarter 2022 core operating margin of 20.6% increased versus the first quarter of 2021 due to operating leverage from higher sales, including the one-time benefit in South Korea, partially offset by increased inflationary impacts. Foreign exchange had a negative 1.3% impact on first quarter 2022 core operating margin. Diluted earnings per share (EPS) First quarter 2022 diluted earnings per share of $0.34 increased 100% on a reported basis and 144% on a constant currency basis. Core diluted earnings per share of $0.68 increased 39% on a reported basis and 56% on a constant currency basis. Dividend On April 27, 2022 at the Company's Annual General Meeting, the shareholders approved a dividend of CHF 0.20 per share, which was paid in May 2022 for an amount of $100 million. Balance sheet and cash flow highlights The Company ended the first quarter with a cash position of $1.0 billion. Cash flows from operations for the first quarter of 2022 totaled $66 million, compared to cash flows from operations of $156 million in the prior year. The current year includes increased cash outflows from changes in net working capital and the timing of tax payments, partially offset by higher sales. Free cash flow(3) amounted to an outflow of $52 million in the first three months of 2022, compared to an inflow of $48 million in the previous year. The decrease in free cash flow was primarily driven by lower cash flows from operating activities. Net cash flows used in investing activities amounted to an outflow of $603 million in the first quarter of 2022, compared to an outflow of $131 million in the prior year, primarily due to the acquisition of Ivantis. Financial debts totaled $4.1 billion, in line with prior year-end. The Company ended the first quarter with a net debt(4) position of $3.1 billion. 2022 outlook The Company updated its full year 2022 outlook as per the table below. This outlook assumes that global markets grow over 2021 reflecting the ongoing market recovery; that current levels of inflation persist for the remainder of the year; and that exchange rates as of mid-April 2022 prevail through year-end.

Ivantis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ivantis Rank

  • When was Ivantis founded?

    Ivantis was founded in 2007.

  • Where is Ivantis's headquarters?

    Ivantis's headquarters is located at 38 Discovery, Irvine.

  • What is Ivantis's latest funding round?

    Ivantis's latest funding round is Acquired.

  • How much did Ivantis raise?

    Ivantis raised a total of $136.3M.

  • Who are the investors of Ivantis?

    Investors of Ivantis include Alcon, Paycheck Protection Program, EDBI, Vertex Ventures HC, RA Capital Management and 9 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.